IFNG and neoplasm: A biomarker analysis of phase 1b OpACIN and phase 2 OpACIN-neo clinical trials (of neoadjuvant nivolumab plus ipilimumab) revealed promising predictive values of the IFN-γ signature score and tumor mutational burden (TMB) in the baseline tumor sample [36].